epinephrine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetic, phenethyl derivatives 1028 51-43-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • epinephrine
  • vasoconstrictine
  • nephridine
  • renoform
  • suprarenin
  • epinephrine bitartrate
  • (-)-adrenaline
  • epinephrine hydrochloride
The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.
  • Molecular weight: 183.21
  • Formula: C9H13NO3
  • CLOGP: -0.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -0.99
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg P
2.24 mg Inhal.aerosol
20 mg Inhal.solution

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.09 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 1948 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 1155.35 34.64 534 3695 101090 2252766
Drug hypersensitivity 783.51 34.64 325 3904 46318 2307538
Accidental exposure to product 635.99 34.64 182 4047 8315 2345541
Device failure 578.78 34.64 124 4105 1641 2352215
Hypotension 569.53 34.64 234 3995 32202 2321654
Cardiac arrest 562.65 34.64 189 4040 14741 2339115
Anaesthetic complication 553.12 34.64 96 4133 359 2353497
Stress cardiomyopathy 520.84 34.64 110 4119 1351 2352505
Anaphylactic reaction 471.13 34.64 149 4080 9556 2344300
Toxicity to various agents 460.35 34.64 202 4027 32552 2321304
Bradycardia 358.05 34.64 122 4107 9859 2343997
Toxic anterior segment syndrome 350.39 34.64 61 4168 232 2353624
Anaphylactic shock 343.27 34.64 97 4132 4189 2349667
Tachycardia 298.94 34.64 122 4107 16287 2337569
Product quality issue 251.34 34.64 96 4133 10733 2343123
Seizure 249.12 34.64 121 4108 24345 2329511
Chondrolysis 232.32 34.64 39 4190 112 2353744
Overdose 222.43 34.64 105 4124 19802 2334054
Incorrect route of product administration 217.87 34.64 72 4157 5264 2348592
Ventricular tachycardia 213.36 34.64 62 4167 2949 2350907
Dyspnoea 203.15 34.64 162 4067 78571 2275285
Expired product administered 198.51 34.64 49 4180 1235 2352621
Loss of consciousness 191.36 34.64 93 4136 18674 2335182
Maternal exposure during pregnancy 186.45 34.64 85 4144 14778 2339078
Generalised tonic-clonic seizure 181.91 34.64 63 4166 5309 2348547
Cyanosis 175.42 34.64 54 4175 3131 2350725
Pulseless electrical activity 168.38 34.64 41 4188 974 2352882
Hypoaesthesia 161.61 34.64 85 4144 20130 2333726
Heart rate increased 159.97 34.64 70 4159 11035 2342821
Ventricular fibrillation 150.04 34.64 44 4185 2157 2351699
Exposure during pregnancy 146.66 34.64 86 4143 25133 2328723
Blood pressure decreased 145.39 34.64 62 4167 9174 2344682
Palpitations 145.30 34.64 74 4155 16382 2337474
Unresponsive to stimuli 145.25 34.64 52 4177 4824 2349032
Cardiogenic shock 144.66 34.64 44 4185 2447 2351409
Kounis syndrome 142.09 34.64 28 4201 234 2353622
Oxygen saturation decreased 136.42 34.64 56 4173 7530 2346326
Injury associated with device 135.81 34.64 37 4192 1384 2352472
Shock 135.67 34.64 47 4182 3957 2349899
Pulmonary oedema 134.60 34.64 55 4174 7308 2346548
Airway peak pressure increased 130.85 34.64 20 4209 23 2353833
Bronchospasm 124.11 34.64 41 4188 2983 2350873
Lagophthalmos 123.39 34.64 21 4208 67 2353789
Methaemoglobinaemia 123.33 34.64 26 4203 313 2353543
Dizziness 118.32 34.64 105 4124 58560 2295296
Circulatory collapse 115.79 34.64 41 4188 3679 2350177
Cauda equina syndrome 113.21 34.64 21 4208 122 2353734
Hypersensitivity 112.77 34.64 71 4158 23522 2330334
Hypertension 112.74 34.64 75 4154 27286 2326570
Erythema 111.04 34.64 72 4157 25087 2328769
Pulse absent 110.72 34.64 29 4200 930 2352926
Blood pressure increased 109.50 34.64 62 4167 16924 2336932
Wrong product administered 109.19 34.64 31 4198 1351 2352505
Respiratory failure 108.31 34.64 57 4172 13471 2340385
Cardio-respiratory arrest 107.33 34.64 50 4179 9096 2344760
Muscular weakness 103.15 34.64 57 4172 14840 2339016
Blood pH decreased 103.07 34.64 24 4205 467 2353389
Accidental overdose 102.06 34.64 38 4191 3934 2349922
Paraesthesia 99.38 34.64 64 4165 22024 2331832
Sinus tachycardia 97.25 34.64 35 4194 3290 2350566
Tremor 95.75 34.64 61 4168 20600 2333256
Respiratory acidosis 90.81 34.64 24 4205 797 2353059
Ophthalmoplegia 90.79 34.64 19 4210 220 2353636
Device malfunction 89.97 34.64 33 4196 3274 2350582
Blood lactic acid increased 89.96 34.64 24 4205 827 2353029
Respiratory arrest 89.05 34.64 39 4190 6139 2347717
Injection site pallor 88.32 34.64 14 4215 24 2353832
Angioedema 86.57 34.64 42 4187 8354 2345502
Coma 86.50 34.64 43 4186 9013 2344843
Post procedural complication 86.03 34.64 31 4198 2923 2350933
Product adhesion issue 85.17 34.64 25 4204 1227 2352629
Headache 84.05 34.64 101 4128 80078 2273778
Injection site pain 83.48 34.64 71 4158 37290 2316566
Mydriasis 82.75 34.64 28 4201 2191 2351665
Supraventricular tachycardia 81.46 34.64 27 4202 1982 2351874
PO2 decreased 79.80 34.64 18 4211 302 2353554
Electrocardiogram ST segment depression 78.88 34.64 20 4209 562 2353294
Chest pain 78.74 34.64 61 4168 28076 2325780
Myocardial ischaemia 78.32 34.64 27 4202 2235 2351621
Depressed level of consciousness 78.27 34.64 38 4191 7566 2346290
Anaphylactoid reaction 78.09 34.64 22 4207 931 2352925
Incorrect dose administered 77.98 34.64 41 4188 9654 2344202
Lung hyperinflation 77.95 34.64 15 4214 109 2353747
Endophthalmitis 77.61 34.64 21 4208 764 2353092
Pallor 75.39 34.64 30 4199 3712 2350144
Hypercapnia 74.96 34.64 19 4210 533 2353323
Electrocardiogram ST segment elevation 73.29 34.64 19 4210 584 2353272
Urticaria 73.15 34.64 55 4174 24206 2329650
Nausea 72.90 34.64 112 4117 112077 2241779
Condition aggravated 71.87 34.64 61 4168 31918 2321938
Nervous system disorder 69.88 34.64 27 4202 3089 2350767
Peripheral ischaemia 69.31 34.64 19 4210 726 2353130
Heart rate decreased 68.97 34.64 28 4201 3648 2350208
Product administration error 67.07 34.64 28 4201 3915 2349941
Pain 66.49 34.64 79 4150 61778 2292078
Arteriospasm coronary 66.19 34.64 18 4211 667 2353189
PCO2 increased 66.13 34.64 14 4215 172 2353684
Product contamination microbial 66.03 34.64 12 4217 61 2353795
Neurotoxicity 64.45 34.64 23 4206 2107 2351749
Medication error 64.17 34.64 31 4198 6100 2347756
Peripheral nerve injury 63.52 34.64 12 4217 78 2353778
Horner's syndrome 62.62 34.64 12 4217 85 2353771
Treatment failure 62.17 34.64 32 4197 7207 2346649
Stridor 61.90 34.64 17 4212 654 2353202
Metabolic acidosis 61.79 34.64 30 4199 5968 2347888
Therapy non-responder 61.56 34.64 33 4196 8071 2345785
Maternal exposure during delivery 61.08 34.64 13 4216 164 2353692
Extremity necrosis 60.62 34.64 14 4215 262 2353594
Musculoskeletal pain 60.35 34.64 36 4193 10794 2343062
Left ventricle outflow tract obstruction 60.35 34.64 11 4218 57 2353799
Respiratory rate increased 59.91 34.64 20 4209 1500 2352356
Pruritus 59.63 34.64 63 4166 43277 2310579
Needle issue 59.57 34.64 18 4211 976 2352880
Rash 58.99 34.64 73 4156 59485 2294371
Injection site ischaemia 58.13 34.64 9 4220 12 2353844
Cataract operation complication 57.39 34.64 10 4219 38 2353818
Corneal oedema 57.24 34.64 14 4215 338 2353518
Agitation 57.11 34.64 35 4194 11016 2342840
Electrocardiogram QT prolonged 57.07 34.64 31 4198 7783 2346073
Blood bicarbonate decreased 57.04 34.64 15 4214 488 2353368
Product complaint 56.91 34.64 26 4203 4512 2349344
No adverse event 56.57 34.64 33 4196 9495 2344361
Status asthmaticus 56.56 34.64 12 4217 149 2353707
Injection site injury 56.36 34.64 13 4216 242 2353614
Tachypnoea 56.05 34.64 21 4208 2208 2351648
Blindness 55.90 34.64 24 4205 3594 2350262
Ventricular extrasystoles 54.87 34.64 20 4209 1946 2351910
Therapeutic product effect prolonged 54.87 34.64 11 4218 101 2353755
Mental status changes 54.74 34.64 27 4202 5555 2348301
Tryptase increased 54.36 34.64 10 4219 55 2353801
Apnoea 53.37 34.64 18 4211 1393 2352463
Procedural complication 53.08 34.64 17 4212 1118 2352738
Conjunctival oedema 52.77 34.64 12 4217 209 2353647
Syncope 52.48 34.64 39 4190 16836 2337020
Haemodynamic instability 52.44 34.64 17 4212 1162 2352694
Vasoconstriction 52.34 34.64 11 4218 130 2353726
Parophthalmia 52.04 34.64 10 4219 72 2353784
Confusional state 51.72 34.64 45 4184 24299 2329557
Drug interaction 50.40 34.64 48 4181 29115 2324741
Hypopyon 50.23 34.64 11 4218 160 2353696
Injection site hypoaesthesia 50.10 34.64 11 4218 162 2353694
Visual acuity reduced 50.10 34.64 25 4204 5273 2348583
Off label use 49.79 34.64 75 4154 73523 2280333
Spinal epidural haemorrhage 49.66 34.64 8 4221 16 2353840
Atrioventricular block complete 49.41 34.64 17 4212 1397 2352459
Ventricular hypokinesia 49.33 34.64 14 4215 608 2353248
Hypoaesthesia oral 49.21 34.64 19 4210 2167 2351689
Hypoxia 49.10 34.64 26 4203 6201 2347655
Sensory loss 48.88 34.64 16 4213 1128 2352728
Injection site coldness 48.70 34.64 9 4220 51 2353805
Malaise 48.49 34.64 64 4165 55521 2298335
Flushing 47.48 34.64 32 4197 11839 2342017
Local anaesthetic systemic toxicity 47.37 34.64 7 4222 5 2353851
Acute pulmonary oedema 47.32 34.64 16 4213 1247 2352609
Hypertensive crisis 46.65 34.64 19 4210 2494 2351362
Hyperhidrosis 46.52 34.64 35 4194 15387 2338469
Asthma 46.45 34.64 31 4198 11283 2342573
Intentional overdose 46.44 34.64 31 4198 11290 2342566
Anxiety 46.37 34.64 46 4183 29313 2324543
Ejection fraction decreased 44.65 34.64 19 4210 2782 2351074
Gait disturbance 44.54 34.64 40 4189 22505 2331351
Myocardial infarction 44.16 34.64 37 4192 18976 2334880
Status epilepticus 43.49 34.64 18 4211 2460 2351396
Acute respiratory failure 43.17 34.64 19 4210 3019 2350837
Wheezing 42.95 34.64 24 4205 6360 2347496
Product use in unapproved indication 41.96 34.64 29 4200 11171 2342685
Ischaemia 41.76 34.64 13 4216 779 2353077
Type I hypersensitivity 41.66 34.64 12 4217 550 2353306
Multiple organ dysfunction syndrome 41.52 34.64 25 4204 7616 2346240
Electrocardiogram QRS complex prolonged 41.44 34.64 14 4215 1088 2352768
Nerve block 40.78 34.64 8 4221 65 2353791
Pharyngeal oedema 40.63 34.64 19 4210 3474 2350382
Vomiting 40.16 34.64 67 4162 71535 2282321
Drug abuse 40.10 34.64 29 4200 11997 2341859
Electrocardiogram T wave inversion 39.95 34.64 12 4217 637 2353219
Hyperaesthesia 39.79 34.64 14 4215 1229 2352627
Chest discomfort 39.37 34.64 31 4198 14564 2339292
Live birth 39.27 34.64 14 4215 1277 2352579
Respiratory distress 39.26 34.64 21 4208 5108 2348748
Procedural pain 38.79 34.64 15 4214 1717 2352139
Retinal artery occlusion 38.73 34.64 10 4219 302 2353554
Troponin I increased 38.58 34.64 10 4219 307 2353549
Skin discolouration 38.17 34.64 21 4208 5399 2348457
Paraplegia 38.17 34.64 11 4218 505 2353351
Joint range of motion decreased 37.79 34.64 15 4214 1841 2352015
Troponin T increased 37.46 34.64 9 4220 201 2353655
Somnolence 37.44 34.64 37 4192 23448 2330408
Anaphylactoid shock 37.36 34.64 8 4221 104 2353752
Eyelid ptosis 37.13 34.64 13 4216 1125 2352731
Brain death 37.08 34.64 11 4218 559 2353297
Toxic epidermal necrolysis 36.25 34.64 17 4212 3127 2350729
Allodynia 36.24 34.64 8 4221 121 2353735
Delirium 36.13 34.64 20 4209 5203 2348653
Left ventricular dysfunction 36.04 34.64 13 4216 1227 2352629
Sensitisation 36.00 34.64 7 4222 54 2353802
Inadequate analgesia 35.98 34.64 11 4218 620 2353236
Sensory disturbance 35.91 34.64 16 4213 2616 2351240
Brain injury 35.84 34.64 12 4217 907 2352949
Device use issue 35.65 34.64 9 4220 248 2353608
Product use issue 35.32 34.64 27 4202 12142 2341714
Spinal anaesthesia 35.28 34.64 6 4223 19 2353837
Wrong technique in product usage process 35.03 34.64 33 4196 19715 2334141
Foetal heart rate abnormal 34.93 34.64 8 4221 144 2353712
Chondromalacia 34.65 34.64 7 4222 67 2353789

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 767.38 41.20 363 2551 63438 1680429
Toxicity to various agents 463.09 41.20 203 2711 28938 1714929
Device failure 417.67 41.20 84 2830 689 1743178
Cardiac arrest 391.71 41.20 152 2762 15778 1728089
Hypotension 364.39 41.20 173 2741 29481 1714386
Anaphylactic reaction 326.02 41.20 104 2810 6009 1737858
Anaesthetic complication 321.35 41.20 57 2857 211 1743656
Accidental exposure to product 295.76 41.20 88 2826 4013 1739854
Anaphylactic shock 270.32 41.20 76 2838 2823 1741044
Overdose 252.95 41.20 113 2801 16588 1727279
Chondrolysis 246.07 41.20 38 2876 39 1743828
Bradycardia 231.74 41.20 93 2821 10441 1733426
Ventricular tachycardia 228.76 41.20 71 2843 3727 1740140
Tachycardia 202.36 41.20 89 2825 12539 1731328
Methaemoglobinaemia 187.12 41.20 38 2876 326 1743541
Loss of consciousness 179.20 41.20 86 2828 14789 1729078
Seizure 172.80 41.20 93 2821 20348 1723519
Needle issue 166.65 41.20 38 2876 587 1743280
Accidental overdose 146.78 41.20 52 2862 4112 1739755
Product quality issue 144.90 41.20 57 2857 6036 1737831
Respiratory arrest 143.70 41.20 56 2858 5783 1738084
Ventricular fibrillation 138.80 41.20 45 2869 2711 1741156
Blood pressure increased 137.99 41.20 65 2849 10688 1733179
Stress cardiomyopathy 135.18 41.20 29 2885 332 1743535
Sinus tachycardia 134.28 41.20 43 2871 2489 1741378
Hypertension 132.87 41.20 77 2837 19371 1724496
Incorrect route of product administration 132.55 41.20 46 2868 3419 1740448
Coma 131.88 41.20 56 2858 7206 1736661
Accidental exposure to product by child 123.13 41.20 31 2883 741 1743126
Toxic anterior segment syndrome 122.56 41.20 24 2890 167 1743700
Unresponsive to stimuli 119.55 41.20 46 2868 4583 1739284
Blood pressure decreased 119.36 41.20 53 2861 7593 1736274
Generalised tonic-clonic seizure 114.55 41.20 43 2871 4003 1739864
Pallor 114.13 41.20 41 2873 3370 1740497
Wrong product administered 110.64 41.20 31 2883 1128 1742739
Pulmonary oedema 107.11 41.20 47 2867 6539 1737328
Expired product administered 104.44 41.20 27 2887 719 1743148
Injection site pallor 103.35 41.20 15 2899 5 1743862
Metabolic acidosis 102.49 41.20 43 2871 5359 1738508
Electrocardiogram ST segment elevation 98.36 41.20 27 2887 909 1742958
Device malfunction 97.62 41.20 32 2882 1992 1741875
Post procedural complication 96.43 41.20 33 2881 2347 1741520
Drug hypersensitivity 95.54 41.20 57 2857 15078 1728789
Circulatory collapse 95.04 41.20 36 2878 3431 1740436
Injury associated with device 92.04 41.20 22 2892 420 1743447
Cardio-respiratory arrest 88.79 41.20 46 2868 9247 1734620
Arteriospasm coronary 86.94 41.20 23 2891 671 1743196
Device use issue 86.88 41.20 15 2899 45 1743822
Apnoea 86.71 41.20 27 2887 1422 1742445
Shock 85.24 41.20 35 2879 4126 1739741
Depressed level of consciousness 84.90 41.20 40 2874 6552 1737315
Mydriasis 84.84 41.20 26 2888 1298 1742569
Electrocardiogram QRS complex prolonged 84.42 41.20 23 2891 752 1743115
Respiratory depression 82.68 41.20 29 2885 2218 1741649
Injection site laceration 81.60 41.20 13 2901 19 1743848
Angioedema 81.45 41.20 44 2870 9620 1734247
Oxygen saturation decreased 81.06 41.20 37 2877 5638 1738229
Heart rate decreased 79.99 41.20 30 2884 2779 1741088
Dyspnoea 79.88 41.20 85 2829 51974 1691893
Injection site injury 77.94 41.20 15 2899 94 1743773
Cyanosis 77.76 41.20 29 2885 2645 1741222
Bronchospasm 77.10 41.20 27 2887 2055 1741812
Heart rate increased 76.21 41.20 37 2877 6473 1737394
Medication error 74.33 41.20 33 2881 4710 1739157
Hypersensitivity 72.86 41.20 42 2872 10402 1733465
Musculoskeletal pain 72.20 41.20 33 2881 5041 1738826
Product administration error 71.41 41.20 28 2886 2925 1740942
Drug abuse 67.25 41.20 44 2870 13645 1730222
Dizziness 67.07 41.20 64 2850 34297 1709570
Ophthalmoplegia 66.26 41.20 15 2899 223 1743644
Hyperhidrosis 65.92 41.20 42 2872 12446 1731421
Urticaria 64.19 41.20 41 2873 12200 1731667
Lagophthalmos 63.70 41.20 11 2903 33 1743834
Vasoplegia syndrome 63.17 41.20 14 2900 188 1743679
Agitation 63.00 41.20 39 2875 10987 1732880
Pulse absent 61.28 41.20 19 2895 985 1742882
Product adhesion issue 60.17 41.20 15 2899 343 1743524
Respiratory distress 59.40 41.20 29 2885 5128 1738739
Hypoxic-ischaemic encephalopathy 59.19 41.20 18 2896 874 1742993
Cauda equina syndrome 59.03 41.20 12 2902 103 1743764
Retinal artery occlusion 58.74 41.20 15 2899 379 1743488
Endophthalmitis 58.63 41.20 17 2897 699 1743168
Hypoxia 58.29 41.20 30 2884 5933 1737934
Brain oedema 57.26 41.20 22 2892 2174 1741693
Erythema 56.35 41.20 40 2874 14148 1729719
Cardiotoxicity 56.19 41.20 17 2897 811 1743056
Electrocardiogram ST segment depression 54.99 41.20 15 2899 492 1743375
Pain 54.53 41.20 51 2863 26606 1717261
Wrong technique in product usage process 54.51 41.20 35 2879 10500 1733367
Paraplegia 53.97 41.20 15 2899 528 1743339
Confusional state 51.97 41.20 45 2869 21233 1722634
Neurotoxicity 51.79 41.20 20 2894 2004 1741863
Myocardial ischaemia 49.31 41.20 22 2892 3171 1740696
Skin laceration 48.83 41.20 19 2895 1942 1741925
Respiratory failure 48.79 41.20 37 2877 14468 1729399
Pulseless electrical activity 48.64 41.20 16 2898 1004 1742863
Drug level increased 45.67 41.20 20 2894 2757 1741110
Delirium 45.43 41.20 26 2888 6336 1737531
Injection site pain 45.20 41.20 31 2883 10369 1733498
Substance abuse 44.90 41.20 15 2899 988 1742879
Nausea 44.71 41.20 63 2851 51133 1692734
Haemodynamic instability 44.40 41.20 16 2898 1321 1742546
Procedural complication 43.33 41.20 15 2899 1101 1742766
Medical device site laceration 43.06 41.20 6 2908 0 1743867
Therapeutic product effect decreased 43.01 41.20 25 2889 6272 1737595
Blindness 42.32 41.20 19 2895 2777 1741090

Pharmacologic Action:

SourceCodeDescription
ATC A01AD01 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC B02BC09 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Local hemostatics
ATC C01CA24 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
ATC R01AA14 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Sympathomimetics, plain
ATC R03AA01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Alpha- and beta-adrenoreceptor agonists
ATC S01EA01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy1)
ATC R03AK01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC S01EA51 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy1)
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
FDA EPC N0000175552 alpha-Adrenergic Agonist
FDA EPC N0000175555 beta-Adrenergic Agonist
FDA EPC N0000175570 Catecholamine
FDA Chemical/Ingredient N0000007715 Catecholamines
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D009184 Mydriatics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D014662 Vasoconstrictor Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Bronchitis indication 32398004 DOID:6132
Anaphylaxis indication 39579001
Local anesthesia, by infiltration indication 44596000
Low blood pressure indication 45007003
Wheezing indication 56018004
Open-angle glaucoma indication 84494001 DOID:1067
Pulmonary emphysema indication 87433001
Dyspnea indication 267036007
Exacerbation of asthma indication 281239006
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Allergic Reactions indication
Administration of Local Anesthetic Nerve Block indication
Ventricular fibrillation off-label use 71908006
Asthma off-label use 195967001 DOID:2841
Local anesthesia off-label use 386761002
Cardiac arrest off-label use 410429000 DOID:0060319
Keratitis contraindication 5888003 DOID:4677
Bacterial septicemia contraindication 10001005 DOID:0040085
Sinus tachycardia contraindication 11092001
Myocardial infarction contraindication 22298006 DOID:5844
Aphakia contraindication 24010005
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Retinal detachment contraindication 42059000 DOID:5327
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Atrial fibrillation contraindication 49436004 DOID:0060224
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Sinus bradycardia contraindication 49710005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Iritis contraindication 65074000 DOID:1406
Cerebral arteriosclerosis contraindication 65312002
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Decreased respiratory function contraindication 80954004
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Partial atrioventricular block contraindication 195039008
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Psychoneurotic personality disorder contraindication 268634009
Deficiency of cholinesterase contraindication 360607009
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Peripheral vascular disease contraindication 400047006
Anterior uveitis contraindication 410692006 DOID:1407
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Denuded skin contraindication 418242004
Thrombosis contraindication 439127006
Occlusive Vascular Disease contraindication
Regional Anesthesia for Labor Pain contraindication
Lidocaine Toxicity contraindication
Pupillary Block Glaucoma contraindication
Reduced Hepatic Blood Flow contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 12.82 acidic
pKa3 13.64 acidic
pKa4 8.71 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9833573 Nov. 23, 2024 METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.3MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9149579 July 19, 2025 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
EQ 0.15MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 0.1MG/DELIVERY AUVI-Q KALEO INC N201739 Nov. 17, 2017 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 0.3MG/DELIVERY AUVI-Q KALEO INC N201739 Aug. 10, 2012 RX SOLUTION INTRAMUSCULAR, SUBCUTANEOUS 9724471 May 23, 2027 METHOD FOR CONFIRMING DOSE DELIVERY
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 10004700 Aug. 14, 2034 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 10039728 Aug. 14, 2034 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
EQ 1MG BASE/ML (EQ 1MG BASE/ML) EPINEPHRINE BELCHER N205029 July 29, 2014 RX SOLUTION INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 9283197 Aug. 15, 2034 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
EQ 1MG BASE/ML (EQ 1MG BASE/ML) ADRENALIN PAR STERILE PRODUCTS N204200 Dec. 7, 2012 RX SOLUTION INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 9295657 March 13, 2035 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
EQ 30MG BASE/30ML (EQ 1MG BASE/ML) ADRENALIN PAR STERILE PRODUCTS N204640 Dec. 18, 2013 RX SOLUTION INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 9295657 March 13, 2035 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.125MG/INH PRIMATENE MIST ARMSTRONG PHARMS N205920 Nov. 7, 2018 OTC AEROSOL, METERED INHALATION Nov. 7, 2021 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1B adrenergic receptor GPCR AGONIST UNKNOWN CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 6.56 DRUG MATRIX CHEMBL
Alpha-1A adrenergic receptor GPCR AGONIST Ki 5.70 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST Ki 6.40 DRUG MATRIX CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST Ki 6.45 DRUG MATRIX CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST Kd 6.20 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR AGONIST UNKNOWN CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.43 PDSP
Beta-1 adrenergic receptor GPCR Ki 5.40 PDSP
D(1A) dopamine receptor GPCR Kd 4.26 CHEMBL
Mu-type opioid receptor GPCR Ki 5.40 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.96 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.14 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.52 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 6.20 CHEMBL
M18 aspartyl aminopeptidase Unclassified IC50 5.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.48 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
Adrenergic receptor alpha-2 GPCR Ki 7.89 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.18 CHEMBL
Adrenergic receptor beta GPCR IC50 4.54 CHEMBL

External reference:

IDSource
D004837 MESH_DESCRIPTOR_UI
4018034 VUID
N0000146377 NUI
C0014563 UMLSCUI
D00996 KEGG_DRUG
30Q7KI53AK UNII
51-42-3 SECONDARY_CAS_RN
387362001 SNOMEDCT_US
65502005 SNOMEDCT_US
3451 MMSL
3992 RXNORM
4663 MMSL
4018034 VANDF
d00699 MMSL
001774 NDDF
5816 PUBCHEM_CID
CHEBI:6213 CHEBI
CHEMBL679 ChEMBL_ID
DB00668 DRUGBANK_ID
2142 INN_ID
479 IUPHAR_LIGAND_ID
CHEMBL1256958 ChEMBL_ID
CHEMBL3183376 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5985 INJECTION 0.15 mg INTRAMUSCULAR ANDA 16 sections
Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5986 INJECTION 0.30 mg INTRAMUSCULAR ANDA 16 sections
epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0115-1694 INJECTION 0.30 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 17 sections
epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0115-1695 INJECTION 0.15 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 17 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0362-0262 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 12 sections
Marcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0557 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 11 sections
Zorcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0830 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 19 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0362-0898 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 12 sections
Lignospan Standard HUMAN PRESCRIPTION DRUG LABEL 1 0362-1095 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 12 sections
Lignospan Forte HUMAN PRESCRIPTION DRUG LABEL 1 0362-1096 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 12 sections
Octocaine 50 HUMAN PRESCRIPTION DRUG LABEL 2 0362-9010 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 12 sections
Vivacaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9011 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 11 sections
Prilocaine Hydrochloride with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9013 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 12 sections
Octocaine 100 HUMAN PRESCRIPTION DRUG LABEL 2 0362-9023 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 12 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9048 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 19 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9049 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 19 sections
LIDOCAINE HUMAN PRESCRIPTION DRUG LABEL 1 0404-6500 INJECTION, SOLUTION 0.02 mg SUBCUTANEOUS ANDA 12 sections
LIDOCAINE HUMAN PRESCRIPTION DRUG LABEL 1 0404-6512 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS ANDA 12 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6620 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 19 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6625 INJECTION, SOLUTION 0.01 mg SUBCUTANEOUS NDA 19 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1209 INJECTION, SOLUTION 5 ug EPIDURAL ANDA 12 sections
Marcaine with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1746 INJECTION, SOLUTION 0.01 mg INFILTRATION NDA 12 sections
Marcaine with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1749 INJECTION, SOLUTION 0.01 mg EPIDURAL NDA 12 sections
Marcaine with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1752 INJECTION, SOLUTION 0.01 mg INFILTRATION NDA 12 sections
Marcaine with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1755 INJECTION, SOLUTION 0.01 mg PERINEURAL NDA 12 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3177 INJECTION, SOLUTION 5 ug INFILTRATION ANDA 12 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3178 INJECTION, SOLUTION 10 ug INFILTRATION ANDA 12 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3181 INJECTION, SOLUTION 5 ug EPIDURAL ANDA 12 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3182 INJECTION, SOLUTION 10 ug INFILTRATION ANDA 12 sections
Lidocaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3183 INJECTION, SOLUTION 5 ug EPIDURAL ANDA 12 sections